Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis
Portal vein tumor thrombosis (PVTT) is one of the most common complications in hepatocellular carcinoma (HCC). HCC with PVTT usually indicates poor prognosis, which has a number of characteristics including a rapidly progressive disease course, worse liver function, complications connected with port...
Gespeichert in:
| Veröffentlicht in: | Journal of cellular physiology 2019-02, Vol.234 (2), p.1062-1070 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1070 |
|---|---|
| container_issue | 2 |
| container_start_page | 1062 |
| container_title | Journal of cellular physiology |
| container_volume | 234 |
| creator | Wang, Jin‐Cheng Xia, An‐Liang Xu, Yong Lu, Xiao‐Jie |
| description | Portal vein tumor thrombosis (PVTT) is one of the most common complications in hepatocellular carcinoma (HCC). HCC with PVTT usually indicates poor prognosis, which has a number of characteristics including a rapidly progressive disease course, worse liver function, complications connected with portal hypertension, and poorer tolerance to treatment. The exact mechanisms of PVTT remain unknown, even though some concerned signal transduction or molecular pathways have been identified. In western countries, sorafenib is the only recommended therapeutic strategy regardless of PVTT types. However, multiple treatment options including transhepatic arterial chemoembolization, hepatectomy, radiotherapy, and sorafenib available in the clinic. In this review, we enumerate and discuss therapeutics against patients with HCC having PVTT available in the clinic and put forward directions for future research.
Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) usually indicates poor prognosis. Sorafenib is the only recommended therapeutic strategy. However, multiple treatment options are available in the clinic. In this review, we enumerate and discuss current methods to treat patients with HCC having PVTT and put forward directions for future research. |
| doi_str_mv | 10.1002/jcp.27324 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2112611391</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2135602323</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3534-e3f63cfa3a5de9c8874651e62c17f81903a12b6726aae2454087ef080648c4273</originalsourceid><addsrcrecordid>eNp10M1LwzAYBvAgipvTg_-AFLzooS5fTdujFD8Z6EHxWLLsLctom5qkG_vvzez0IHjK4f3x8ORB6JzgG4Ixna5Ud0NTRvkBGhOcpzEXCT1E43AjcZ5wMkInzq0wxnnO2DEaMUwTwXE-Rh-FaToLS2idXkPkLUjfQOtdVBkbLaGT3iio676WNlLSKt2aRkYb7ZdRZ6yXdbQG3Ua-b4L3S2uauXHanaKjStYOzvbvBL3f370Vj_Hs5eGpuJ3FiiWMx8AqwVQlmUwWkKssS0N1AoIqklYZyTGThM5FSoWUQHnCcZZChTMseKZ4-PMEXQ25nTWfPThfNtrtCssWTO9KSggVhLCcBHr5h65Mb9vQLiiWCEwZZUFdD0pZ45yFquysbqTdlgSXu7XLsHb5vXawF_vEft7A4lf-zBvAdAAbXcP2_6TyuXgdIr8AMZOItA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2135602323</pqid></control><display><type>article</type><title>Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Wang, Jin‐Cheng ; Xia, An‐Liang ; Xu, Yong ; Lu, Xiao‐Jie</creator><creatorcontrib>Wang, Jin‐Cheng ; Xia, An‐Liang ; Xu, Yong ; Lu, Xiao‐Jie</creatorcontrib><description>Portal vein tumor thrombosis (PVTT) is one of the most common complications in hepatocellular carcinoma (HCC). HCC with PVTT usually indicates poor prognosis, which has a number of characteristics including a rapidly progressive disease course, worse liver function, complications connected with portal hypertension, and poorer tolerance to treatment. The exact mechanisms of PVTT remain unknown, even though some concerned signal transduction or molecular pathways have been identified. In western countries, sorafenib is the only recommended therapeutic strategy regardless of PVTT types. However, multiple treatment options including transhepatic arterial chemoembolization, hepatectomy, radiotherapy, and sorafenib available in the clinic. In this review, we enumerate and discuss therapeutics against patients with HCC having PVTT available in the clinic and put forward directions for future research.
Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) usually indicates poor prognosis. Sorafenib is the only recommended therapeutic strategy. However, multiple treatment options are available in the clinic. In this review, we enumerate and discuss current methods to treat patients with HCC having PVTT and put forward directions for future research.</description><identifier>ISSN: 0021-9541</identifier><identifier>EISSN: 1097-4652</identifier><identifier>DOI: 10.1002/jcp.27324</identifier><identifier>PMID: 30256409</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Animals ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - therapy ; Chemoembolization, Therapeutic - adverse effects ; Chemoembolization, Therapeutic - mortality ; Hepatectomy ; Hepatectomy - adverse effects ; Hepatectomy - mortality ; Hepatocellular carcinoma ; hepatocellular carcinoma (HCC) ; Humans ; Hypertension ; Liver ; Liver cancer ; Liver diseases ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Liver Neoplasms - therapy ; Portal vein ; Portal Vein - pathology ; portal vein tumor thrombosis ; Radiation therapy ; Radiotherapy ; Signal transduction ; sorafenib ; Sorafenib - adverse effects ; Sorafenib - therapeutic use ; Targeted cancer therapy ; Thromboembolism ; Thrombosis ; transhepatic arterial chemoembolization ; Treatment Outcome ; Tumors ; Venous Thrombosis - mortality ; Venous Thrombosis - pathology ; Venous Thrombosis - therapy</subject><ispartof>Journal of cellular physiology, 2019-02, Vol.234 (2), p.1062-1070</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3534-e3f63cfa3a5de9c8874651e62c17f81903a12b6726aae2454087ef080648c4273</citedby><cites>FETCH-LOGICAL-c3534-e3f63cfa3a5de9c8874651e62c17f81903a12b6726aae2454087ef080648c4273</cites><orcidid>0000-0002-1595-6414</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcp.27324$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcp.27324$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30256409$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Jin‐Cheng</creatorcontrib><creatorcontrib>Xia, An‐Liang</creatorcontrib><creatorcontrib>Xu, Yong</creatorcontrib><creatorcontrib>Lu, Xiao‐Jie</creatorcontrib><title>Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis</title><title>Journal of cellular physiology</title><addtitle>J Cell Physiol</addtitle><description>Portal vein tumor thrombosis (PVTT) is one of the most common complications in hepatocellular carcinoma (HCC). HCC with PVTT usually indicates poor prognosis, which has a number of characteristics including a rapidly progressive disease course, worse liver function, complications connected with portal hypertension, and poorer tolerance to treatment. The exact mechanisms of PVTT remain unknown, even though some concerned signal transduction or molecular pathways have been identified. In western countries, sorafenib is the only recommended therapeutic strategy regardless of PVTT types. However, multiple treatment options including transhepatic arterial chemoembolization, hepatectomy, radiotherapy, and sorafenib available in the clinic. In this review, we enumerate and discuss therapeutics against patients with HCC having PVTT available in the clinic and put forward directions for future research.
Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) usually indicates poor prognosis. Sorafenib is the only recommended therapeutic strategy. However, multiple treatment options are available in the clinic. In this review, we enumerate and discuss current methods to treat patients with HCC having PVTT and put forward directions for future research.</description><subject>Animals</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Chemoembolization, Therapeutic - adverse effects</subject><subject>Chemoembolization, Therapeutic - mortality</subject><subject>Hepatectomy</subject><subject>Hepatectomy - adverse effects</subject><subject>Hepatectomy - mortality</subject><subject>Hepatocellular carcinoma</subject><subject>hepatocellular carcinoma (HCC)</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver diseases</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - therapy</subject><subject>Portal vein</subject><subject>Portal Vein - pathology</subject><subject>portal vein tumor thrombosis</subject><subject>Radiation therapy</subject><subject>Radiotherapy</subject><subject>Signal transduction</subject><subject>sorafenib</subject><subject>Sorafenib - adverse effects</subject><subject>Sorafenib - therapeutic use</subject><subject>Targeted cancer therapy</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><subject>transhepatic arterial chemoembolization</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Venous Thrombosis - mortality</subject><subject>Venous Thrombosis - pathology</subject><subject>Venous Thrombosis - therapy</subject><issn>0021-9541</issn><issn>1097-4652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10M1LwzAYBvAgipvTg_-AFLzooS5fTdujFD8Z6EHxWLLsLctom5qkG_vvzez0IHjK4f3x8ORB6JzgG4Ixna5Ud0NTRvkBGhOcpzEXCT1E43AjcZ5wMkInzq0wxnnO2DEaMUwTwXE-Rh-FaToLS2idXkPkLUjfQOtdVBkbLaGT3iio676WNlLSKt2aRkYb7ZdRZ6yXdbQG3Ua-b4L3S2uauXHanaKjStYOzvbvBL3f370Vj_Hs5eGpuJ3FiiWMx8AqwVQlmUwWkKssS0N1AoIqklYZyTGThM5FSoWUQHnCcZZChTMseKZ4-PMEXQ25nTWfPThfNtrtCssWTO9KSggVhLCcBHr5h65Mb9vQLiiWCEwZZUFdD0pZ45yFquysbqTdlgSXu7XLsHb5vXawF_vEft7A4lf-zBvAdAAbXcP2_6TyuXgdIr8AMZOItA</recordid><startdate>201902</startdate><enddate>201902</enddate><creator>Wang, Jin‐Cheng</creator><creator>Xia, An‐Liang</creator><creator>Xu, Yong</creator><creator>Lu, Xiao‐Jie</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1595-6414</orcidid></search><sort><creationdate>201902</creationdate><title>Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis</title><author>Wang, Jin‐Cheng ; Xia, An‐Liang ; Xu, Yong ; Lu, Xiao‐Jie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3534-e3f63cfa3a5de9c8874651e62c17f81903a12b6726aae2454087ef080648c4273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Chemoembolization, Therapeutic - adverse effects</topic><topic>Chemoembolization, Therapeutic - mortality</topic><topic>Hepatectomy</topic><topic>Hepatectomy - adverse effects</topic><topic>Hepatectomy - mortality</topic><topic>Hepatocellular carcinoma</topic><topic>hepatocellular carcinoma (HCC)</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver diseases</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - therapy</topic><topic>Portal vein</topic><topic>Portal Vein - pathology</topic><topic>portal vein tumor thrombosis</topic><topic>Radiation therapy</topic><topic>Radiotherapy</topic><topic>Signal transduction</topic><topic>sorafenib</topic><topic>Sorafenib - adverse effects</topic><topic>Sorafenib - therapeutic use</topic><topic>Targeted cancer therapy</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><topic>transhepatic arterial chemoembolization</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Venous Thrombosis - mortality</topic><topic>Venous Thrombosis - pathology</topic><topic>Venous Thrombosis - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Jin‐Cheng</creatorcontrib><creatorcontrib>Xia, An‐Liang</creatorcontrib><creatorcontrib>Xu, Yong</creatorcontrib><creatorcontrib>Lu, Xiao‐Jie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cellular physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Jin‐Cheng</au><au>Xia, An‐Liang</au><au>Xu, Yong</au><au>Lu, Xiao‐Jie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis</atitle><jtitle>Journal of cellular physiology</jtitle><addtitle>J Cell Physiol</addtitle><date>2019-02</date><risdate>2019</risdate><volume>234</volume><issue>2</issue><spage>1062</spage><epage>1070</epage><pages>1062-1070</pages><issn>0021-9541</issn><eissn>1097-4652</eissn><abstract>Portal vein tumor thrombosis (PVTT) is one of the most common complications in hepatocellular carcinoma (HCC). HCC with PVTT usually indicates poor prognosis, which has a number of characteristics including a rapidly progressive disease course, worse liver function, complications connected with portal hypertension, and poorer tolerance to treatment. The exact mechanisms of PVTT remain unknown, even though some concerned signal transduction or molecular pathways have been identified. In western countries, sorafenib is the only recommended therapeutic strategy regardless of PVTT types. However, multiple treatment options including transhepatic arterial chemoembolization, hepatectomy, radiotherapy, and sorafenib available in the clinic. In this review, we enumerate and discuss therapeutics against patients with HCC having PVTT available in the clinic and put forward directions for future research.
Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) usually indicates poor prognosis. Sorafenib is the only recommended therapeutic strategy. However, multiple treatment options are available in the clinic. In this review, we enumerate and discuss current methods to treat patients with HCC having PVTT and put forward directions for future research.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30256409</pmid><doi>10.1002/jcp.27324</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-1595-6414</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9541 |
| ispartof | Journal of cellular physiology, 2019-02, Vol.234 (2), p.1062-1070 |
| issn | 0021-9541 1097-4652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2112611391 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Animals Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Chemoembolization, Therapeutic - adverse effects Chemoembolization, Therapeutic - mortality Hepatectomy Hepatectomy - adverse effects Hepatectomy - mortality Hepatocellular carcinoma hepatocellular carcinoma (HCC) Humans Hypertension Liver Liver cancer Liver diseases Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - therapy Portal vein Portal Vein - pathology portal vein tumor thrombosis Radiation therapy Radiotherapy Signal transduction sorafenib Sorafenib - adverse effects Sorafenib - therapeutic use Targeted cancer therapy Thromboembolism Thrombosis transhepatic arterial chemoembolization Treatment Outcome Tumors Venous Thrombosis - mortality Venous Thrombosis - pathology Venous Thrombosis - therapy |
| title | Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T10%3A14%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comprehensive%20treatments%20for%20hepatocellular%20carcinoma%20with%20portal%20vein%20tumor%20thrombosis&rft.jtitle=Journal%20of%20cellular%20physiology&rft.au=Wang,%20Jin%E2%80%90Cheng&rft.date=2019-02&rft.volume=234&rft.issue=2&rft.spage=1062&rft.epage=1070&rft.pages=1062-1070&rft.issn=0021-9541&rft.eissn=1097-4652&rft_id=info:doi/10.1002/jcp.27324&rft_dat=%3Cproquest_cross%3E2135602323%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2135602323&rft_id=info:pmid/30256409&rfr_iscdi=true |